A new subcutaneous version of the checkpoint blocker Opdivo (nivolumab) could be approved earlier than expected, after the US regular brought forward the date f 22 May 2024
Japanese drugmaker Ono Pharmaceutical has received supplemental approvals for the BRAF inhibitor Braftovi (encorafenib), and the MEK inhibitor Mektovi (binimeti 17 May 2024
A US Food and Drug Administration (FDA) panel will consider Lykos Therapeutics’ filing for midomafetamine capsules (MDMA) as a therapy-assisted treatment for po 15 May 2024
Japanese drugmaker Eisai has started the rolling submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Leqembi (l 15 May 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.